Multi-gene targeted antiangiogenic therapies for experimental corneal neovascularization

Molecular Vision

Volumn 16, Issue , 2010, Pages 310-319

  Chen, Peng ^a   Yin, Hongmei ^a   Wang, Yao ^a   Mi, Jing ^b   He, Wenxiao ^a   Xie, Lixin ^a   Wang, Yiqiang ^a  

^a SHANDONG EYE INSTITUTE   (China)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOPOIETIN RECEPTOR; ENDOSTATIN; RETROVIRUS VECTOR; VASCULOTROPIN RECEPTOR 2; ALKALI; ANGIOGENIC FACTOR; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIANGIOGENIC GENE THERAPY; ARTICLE; CELL MIGRATION; CELL PROLIFERATION; CHEMICAL BURN; CONTROLLED STUDY; CORNEA NEOVASCULARIZATION; DRUG MECHANISM; ENDOTHELIUM CELL; FEMALE; GENE TARGETING; HUMAN; HUMAN CELL; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UMBILICAL VEIN; VIRUS PARTICLE; ANIMAL; BURN; CELL MOTION; CHEMICALLY INDUCED DISORDER; GENE THERAPY; GENETICS; INFLAMMATION; METABOLISM; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; SIGNAL TRANSDUCTION; WESTERN BLOTTING;

ALKALIES; ANGIOGENESIS INDUCING AGENTS; ANIMALS; BLOTTING, WESTERN; BURNS; CELL MOVEMENT; CELL PROLIFERATION; CORNEAL NEOVASCULARIZATION; ENDOTHELIAL CELLS; GENE THERAPY; HUMANS; INFLAMMATION; MICE; NEOVASCULARIZATION, PATHOLOGIC; NF-KAPPA B; SIGNAL TRANSDUCTION;

EID: 77952306182     PISSN: None     EISSN: 10900535     Source Type: Journal    
DOI: None     Document Type: Article

References (54)

1. Usui T, Sugisaki K, Iriyama A, Yokoo S, Yamagami S, Nagai N, Ishida S, Amano S. Inhibition of corneal neovascularization by blocking the angiotensin II type 1 receptor. Invest Ophthalmol Vis Sci 2008; 49:4370-4376. [PMID: 18829859]
2. Mochimaru H, Usui T, Yaguchi T, Nagahama Y, Hasegawa G, Usui Y, Shimmura S, Tsubota K, Amano S, Kawakami Y, Ishida S. Suppression of alkali burn-induced corneal neovascularization by dendritic cell vaccination targeting VEGF receptor 2. Invest Ophthalmol Vis Sci 2008; 49:2172-2177. [PMID: 18263815]
3. Lai LJ, Xiao X, Wu JH. Inhibition of corneal neovascularization with endostatin delivered by adeno-associated viral (AAV) vector in a mouse corneal injury model. J Biomed Sci 2007; 14:313-322. [PMID: 17373573]
4. Gan L, Fagerholm P, Palmblad J. Vascular endothelial growth factor (VEGF) and its receptor VEGFR-2 in the regulation of corneal neovascularization and wound healing. Acta Ophthalmol Scand 2004; 82:557-563. [PMID: 15453853]
5. Singh N, Amin S, Richter E, Rashid S, Scoglietti V, Jani PD, Wang J, Kaur R, Ambati J, Dong Z, Ambati BK. Flt-1 intraceptors inhibit hypoxia-induced VEGF expression in vitro and corneal neovascularization in vivo. Invest Ophthalmol Vis Sci 2005; 46:1647-1652. [PMID: 15851564]
6. Ma X, Ottino P, Bazan HE, Bazan NG. Platelet-activating factor (PAF) induces corneal neovascularization and upregulates VEGF expression in endothelial cells. Invest Ophthalmol Vis Sci 2004; 45:2915-2921. [PMID: 15326102]
7. Bock F, Onderka J, Rummelt C, Dietrich T, Bachmann B, Kruse FE, Schlotzer-Schrehardt UM, Cursiefen C. Safety profile of topical VEGF-neutralization at the cornea. Invest Ophthalmol Vis Sci 2009; 50:2095-2102. [PMID: 19151400]
8. Chen WL, Lin CT, Lin NT, Tu IH, Li JW, Chow LP, Liu KR, Hu FR. Subconjunctival injection of Bevacizumab (Avastin) inhibits corneal neovascularization in different rabbit models of corneal angiogenesis. Invest Ophthalmol Vis Sci 2009; 50:1659-1665. [PMID: 18997093]
9. Berdugo M, Valamanesh F, Andrieu C, Klein C, Benezra D, Courtois Y, Behar-Cohen F. Delivery of antisense oligonucleotide to the cornea by iontophoresis. Antisense Nucleic Acid Drug Dev 2003; 13:107-114. [PMID: 12804037]
10. Agostini H, Boden K, Unsold A, Martin G, Hansen L, Fiedler U, Esser N, Marme D. A single local injection of recombinant VEGF receptor 2 but not of Tie2 inhibits retinal neovascularization in the mouse. Curr Eye Res 2005; 30:249-257. [PMID: 15823917]
11. Willis MC, Collins BD, Zhang T, Green LS, Sebesta DP, Bell C, Kellogg E, Gill SC, Magallanez A, Knauer S, Bendele RA, Gill PS, Janjic N. Liposome-anchored vascular endothelial growth factor aptamers. Bioconjug Chem 1998; 9:573-582. [PMID: 9736491]
12. Chariot A, Meuwis MA, Bonif M, Leonardi A, Merville MP, Gielen J, Piette J, Siebenlist U, Bours V. NF-kappaB activating scaffold proteins as signaling molecules and putative therapeutic targets. Curr Med Chem 2003; 10:593-602. [PMID: 12678791]
13. De Martin R, Hoeth M, Hofer-Warbinek R, Schmid JA. The transcription factor NF-kappa B and the regulation of vascular cell function. Arterioscler Thromb Vasc Biol 2000; 20:E83-E88. [PMID: 11073859]
14. Josko J, Mazurek M. Transcription factors having impact on vascular endothelial growth factor (VEGF) gene expression in angiogenesis. Med Sci Monit 2004; 10:RA89-RA98. [PMID: 15039660]
15. Sasaki H, Zhu L, Fukuda S, Maulik N. Inhibition of NF kappa B activation by pyrrolidine dithiocarbamate prevents in vivo hypoxia/reoxygenation-mediated myocardial angiogenesis. Int J Tissue React 2000; 22:93-100. [PMID: 11199341]
16. O'Reilly MS, Boehm T, Shing Y, Fukai N, Vasios G, Lane WS, Flynn E, Birkhead JR, Olsen BR, Folkman J. Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 1997; 88:277-285. [PMID: 9008168]
17. Murthy RC, McFarland TJ, Yoken J, Chen S, Barone C, Burke D, Zhang Y, Appukuttan B, Stout JT. Corneal transduction to inhibit angiogenesis and graft failure. Invest Ophthalmol Vis Sci 2003; 44:1837-1842. [PMID: 12714613]
18. Davis S, Aldrich TH, Jones PF, Acheson A, Compton DL, Jain V, Ryan TE, Bruno J, Radziejewski C, Maisonpierre PC, Yancopoulos GD. Isolation of angiopoietin-1, a ligand for the TIE2 receptor, by secretion-trap expression cloning. Cell 1996; 87:1161-1169. [PMID: 8980223]
19. Maisonpierre PC, Suri C, Jones PF, Bartunkova S, Wiegand SJ, Radziejewski C, Compton D, McClain J, Aldrich TH, Papadopoulos N, Daly TJ, Davis S, Sato TN, Yancopoulos GD. Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science 1997; 277:55-60. [PMID: 9204896]
20. Suri C, Jones PF, Patan S, Bartunkova S, Maisonpierre PC, Davis S, Sato TN, Yancopoulos GD. Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis. Cell 1996; 87:1171-1180. [PMID: 8980224]
21. Raikwar SP, Temm CJ, Raikwar NS, Kao C, Molitoris BA, Gardner TA. Adenoviral vectors expressing human endostatin-angiostatin and soluble Tie2: enhanced suppression of tumor growth and antiangiogenic effects in a prostate tumor model. Mol Ther 2005; 12:1091-1100. [PMID: 16169279]
22. White RR, Shan S, Rusconi CP, Shetty G, Dewhirst MW, Kontos CD, Sullenger BA. Inhibition of rat corneal angiogenesis by a nuclease-resistant RNA aptamer specific for angiopoietin-2. Proc Natl Acad Sci USA 2003; 100:5028-5033. [PMID: 12692304]
23. Bradley J, Ju M, Robinson GS. Combination therapy for the treatment of ocular neovascularization. Angiogenesis 2007; 10:141-148. [PMID: 17372853]
24. Mi J, Sarraf-Yazdi S, Zhang X, Cao Y, Dewhirst MW, Kontos CD, Li CY, Clary BM. A comparison of antiangiogenic therapies for the prevention of liver metastases. J Surg Res 2006; 131:97-104. [PMID: 16242720]
25. Kou B, Li Y, Shi Y, Xia J, Wang X, Wu S. Gene therapeutic exploration: retrovirus-mediated soluble vascular endothelial growth factor receptor-2 (sFLK-1) inhibits the tumorigenicity of S180, MCF-7, and B16 cells in vivo. Oncol Res 2005; 15:239-247. [PMID: 16261843]
26. Albert DM, Scheef EA, Wang S, Mehraein F, Darjatmoko SR, Sorenson CM, Sheibani N. Calcitriol is a potent inhibitor of retinal neovascularization. Invest Ophthalmol Vis Sci 2007; 48:2327-2334. [PMID: 17460298]
27. Totan Y, Aydin E, Cekic O, Cihan Dagloglu M, Borazan M, Daglioglu K, Gultek A. Effect of caffeic acid phenethyl ester on corneal neovascularization in rats. Curr Eye Res 2001; 23:291-297. [PMID: 11852431]
28. Mori K, Duh E, Gehlbach P, Ando A, Takahashi K, Pearlman J, Yang HS, Zack DJ, Ettyreddy D, Brough DE, Wei LL, Campochiaro PA. Pigment epithelium-derived factor inhibits retinal and choroidal neovascularization. J Cell Physiol 2001; 188:253-263. [PMID: 11424092]
29. Largiader T, Eto M, Payeli SK, Greutert H, Viswambharan H, Lachat M, Zund G, Yang Z, Tanner FC, Luscher TF. Endothelial nitric oxide synthase gene transfer inhibits human smooth muscle cell migration via inhibition of Rho A. J Cardiovasc Pharmacol 2008; 52:369-374. [PMID: 18841072]
30. Wilson SE, Mohan RR, Ambrosio R Jr, Hong J, Lee J. The corneal wound healing response: cytokine-mediated interaction of the epithelium, stroma, and inflammatory cells. Prog Retin Eye Res 2001; 20:625-637. [PMID: 11470453]
31. Gan L, Fagerholm P. Leukocytes in the early events of corneal neovascularization. Cornea 2001; 20:96-99. [PMID: 11189012]
32. Mohan RR, Schultz GS, Hong JW, Wilson SE. Gene transfer into rabbit keratocytes using AAV and lipid-mediated plasmid DNA vectors with a lamellar flap for stromal access. Exp Eye Res 2003; 76:373-383. [PMID: 12573666]
33. Hudde T, Rayner SA, De Alwis M, Thrasher AJ, Smith J, Coffin RS, George AJ, Larkin DF. Adeno-associated and herpes simplex viruses as vectors for gene transfer to the corneal endothelium. Cornea 2000; 19:369-373. [PMID: 10832701]
34. Wang X, Appukuttan B, Ott S, Patel R, Irvine J, Song J, Park JH, Smith R, Stout JT. Efficient and sustained transgene expression in human corneal cells mediated by a lentiviral vector. Gene Ther 2000; 7:196-200. [PMID: 10694795]
35. Afzal A, Shaw LC, Ljubimov AV, Boulton ME, Segal MS, Grant MB. Retinal and choroidal microangiopathies: therapeutic opportunities. Microvasc Res 2007; 74:131-144. [PMID: 17585951]
36. Dorrell MI, Aguilar E, Scheppke L, Barnett FH, Friedlander M. Combination angiostatic therapy completely inhibits ocular and tumor angiogenesis. Proc Natl Acad Sci USA 2007; 104:967-972. [PMID: 17210921]
37. Friedlander M. Combination angiostatic therapies: targeting multiple angiogenic pathways. Retina 2009; 29:S27-S29. [PMID: 19553794]
38. Athanassiades A, Hamilton GS, Lala PK. Vascular endothelial growth factor stimulates proliferation but not migration or invasiveness in human extravillous trophoblast. Biol Reprod 1998; 59:643-654. [PMID: 9716565]
39. Zeng H, Sanyal S, Mukhopadhyay D. Tyrosine residues 951 and 1059 of vascular endothelial growth factor receptor-2 (KDR) are essential for vascular permeability factor/vascular endothelial growth factor-induced endothelium migration and proliferation, respectively. J Biol Chem 2001; 276:32714-32719. [PMID: 11435426]
40. Moses MA. The regulation of neovascularization of matrix metalloproteinases and their inhibitors. Stem Cells 1997; 15:180-189. [PMID: 9170209]
41. Dinarello CA. Biologic basis for interleukin-1 in disease. Blood 1996; 87:2095-2147. [PMID: 8630372]
42. Dana MR, Zhu SN, Yamada J. Topical modulation of interleukin-1 activity in corneal neovascularization. Cornea 1998; 17:403-409. [PMID: 9676913]
43. Fukuda M, Mishima H, Otori T. Detection of interleukin-1 beta in the tear fluid of patients with corneal disease with or without conjunctival involvement. Jpn J Ophthalmol 1997; 41:63-66. [PMID: 9152805]
44. Saika S, Miyamoto T, Yamanaka O, Kato T, Ohnishi Y, Flanders KC, Ikeda K, Nakajima Y, Kao WW, Sato M, Muragaki Y, Ooshima A. Therapeutic effect of topical administration of SN50, an inhibitor of nuclear factorkappaB, in treatment of corneal alkali burns in mice. Am J Pathol 2005; 166:1393-1403. [PMID: 15855640]
45. Lu Y, Fukuda K, Liu Y, Kumagai N, Nishida T. Dexamethasone inhibition of IL-1-induced collagen degradation by corneal fibroblasts in three-dimensional culture. Invest Ophthalmol Vis Sci 2004; 45:2998-3004. [PMID: 15326113]
46. Kim H, Koh G. Lipopolysaccharide activates matrix metalloproteinase-2 in endothelial cells through an NFkappaB-dependent pathway. Biochem Biophys Res Commun 2000; 269:401-405. [PMID: 10708565]
47. Joyce D, Albanese C, Steer J, Fu M, Bouzahzah B, Pestell RG. NF-kappaB and cell-cycle regulation: the cyclin connection. Cytokine Growth Factor Rev 2001; 12:73-90. [PMID: 11312120]
48. Han S, Yoon K, Lee K, Kim K, Jang H, Lee NK, Hwang K, Young Lee S. TNF-related weak inducer of apoptosis receptor, a TNF receptor superfamily member, activates NFkappa B through TNF receptor-associated factors. Biochem Biophys Res Commun 2003; 305:789-796. [PMID: 12767899]
49. Ramanathan M, Pinhal-Enfield G, Hao I, Leibovich SJ. Synergistic up-regulation of vascular endothelial growth factor (VEGF) expression in macrophages by adenosine A2A receptor agonists and endotoxin involves transcriptional regulation via the hypoxia response element in the VEGF promoter. Mol Biol Cell 2007; 18:14-23. [PMID: 17065555]
50. Minami T, Miura M, Aird WC, Kodama T. Thrombin-induced autoinhibitory factor, Down syndrome critical region-1, attenuates NFAT-dependent vascular cell adhesion molecule-1 expression and inflammation in the endothelium. J Biol Chem 2006; 281:20503-20520. [PMID: 16627481]
51. Tong Q, Zheng L, Lin L, Li B, Wang D, Huang C, Li D. VEGF is upregulated by hypoxia-induced mitogenic factor via the PI-3K/Akt-NF-kappaB signaling pathway. Respir Res 2006; 7:37. [PMID: 16512910]
52. Ko HM, Jung HH, Seo KH, Kang YR, Kim HA, Park SJ, Lee HK, Im SY. Platelet-activating factor-induced NF-kappaB activation enhances VEGF expression through a decrease in p53 activity. FEBS Lett 2006; 580:3006-3012. [PMID: 16684540]
53. Wang Z, Banerjee S, Li Y, Rahman KM, Zhang Y, Sarkar FH. Down-regulation of notch-1 inhibits invasion by inactivation of nuclear factor-kappaB, vascular endothelial growth factor, and matrix metalloproteinase-9 in pancreatic cancer cells. Cancer Res 2006; 66:2778-2784. [PMID: 16510599]
54. Yoshida S, Ono M, Shono T, Izumi H, Ishibashi T, Suzuki H, Kuwano M. Involvement of interleukin-8, vascular endothelial growth factor, and basic fibroblast growth factor in tumor necrosis factor alpha-dependent angiogenesis. Mol Cell Biol 1997; 17:4015-4023. [PMID: 9199336]